A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Conditions
Clear Cell Renal Cell Cancer (ccRCC) · Pancreatic Ductal Adenocarcinoma (PDAC) · Colorectal Cancer (CRC) · Urothelial Carcinoma (UC) · Indeterminate Renal Mass (IDRM) · Muscle Invasive Bladder Cancer (MIBC) · Head and Neck Cancer (H&N) · Triple Negative Breast Cancer (TNBC) · Squamous Non-Small Cell Lung Cancer (NSCLC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Peter MacCallum Cancer Centre, Melbourne, Australia
UNSW Sydney, St Vincent's Hospital Sydney, Sydney, Australia
Centre Jean Perrin, Clermont-Ferrand, France
Centre Georges François Leclerc, Dijon, France
CHU de Grenoble-Alpes, Boulevard de la Chantourne, Grenoble, France
Centre Léon Bérard, Lyon, France
AP-HM - Hopital de la Timone, Marseille, France
CHU de Nantes, Nantes, France
IUCT - Oncopole, Toulouse, France
CHRU de Nancy - Hopitaux de Brabois, Vandœuvre-lès-Nancy, France